Waters Corporation announced the launch of the Waters Cyclic IMS P20 Mass Spectrometer at ASMS 2026. The high-resolution structural and spatial omics platform is designed to help scientists see biology more clearly, and act on it faster.
Combining multipass Cyclic Ion Mobility Spectrometry with an enhanced suite of fragmentation, probing, and imaging capabilities, this instrument delivers confident insights for the early detection of disease signals, from protein misfolding to post-translational modifications. The system includes full‑spectrum molecular imaging.
As researchers pursue larger and more heterogeneous therapeutic targets, analytical workflows need higher sensitivity, higher structural resolution, and easier-to-adopt methods. The Cyclic IMS P20 Mass Spectrometer meets that need with a more than a 10-fold increase in MS/MS sensitivity compared to its predecessor (based on Waters data), an upper mass range extended by more than 50% to over 100 kDa, and a set of complementary structural probing approaches, including tandem ion mobility spectrometry (IMSn), electron-capture dissociation (ECD), surface-induced dissociation (SID), and collision-induced unfolding (CIU).
The Cyclic IMS P20 Mass Spectrometer also brings Matrix-Assisted Laser Desorption/Ionization (MALDI) and Desorption Electrospray Ionization (DESI) imaging sources together in one system, pioneering their combination with advanced multipass cyclic ion mobility and IMS separation to help researchers see more, with greater clarity, directly in their samples. This approach broadens coverage across small molecules, lipids, peptides, and proteins, while separating isobaric and stereoisomeric compounds. Additionally, the system delivers multi-dimensional insights that elucidate links between molecular composition and the tissue microenvironment, supporting biomarker identification directly from tissue.
The Waters Cyclic IMS P20 Mass Spectrometer is expected to be available globally beginning September 2026.
